NOVEL OSTEOINDUCTIVE COMPOSITIONS

Abstract: Human and bovine bone inductive factor products and processes. The factors may be produced by recombinant techniques and are useful in the research and treatment of bone and periodontal defects.

Description: NOVEL OSTEOINDUCTIVE COMPOSITIONS The present invention relates to novel proteins and processes for obtaining them. These proteins are capable of inducing cartilage and bone formation. Background Bone is a highly specialized tissue characterized by an extensive matrix structure formed of fibrous bundles of the protein collagen, and proteoglycans, noncollagenous proteins, lipids and acidic proteins. The processes of bone formation and ' renewal/repair of bone tissue, which occur continuously throughout- life, are performed by specialized cells. Normal embryonic long bone development is preceded by formation of a cartilage- model. Bone growth is presumably mediated by "dsteoblasts" (bone-forming cells) , while remodeling of bone is apparently accomplished by the joint activities of bone-resorbing cells, called "osteoσlasts" and osteoblasts. A variety of osteogenic, cartilage-inducing and bone inducing factors have been described. See, e.g. European patent applications 148,155 and 169,016 for discussions thereof. Brief Description of the Invention The present invention provides novel proteins in purified form. Specifically, four of the novel proteins are designated BMP-1, BMP-2 Class I (or BMP-2), BMP-3, and BMP-2 Class II (or BMP-4) wherein BMP is bone morphogeniσ protein. These proteins are- characterized by peptide sequences the same as or substantially homologous to amino acid sequences illustrated in Tables II through VIII below. They are capable of inducing bone-formation at a predetermined site. These bone inductive factors are further characterized by biochemical and biological characteristics including activity at a concentration of 10 to lOOOng/gra of bone in an .in vivo rat bone formation assay described below. Proteins of this invention may be encoded by the DNA sequences depicted in the Tables or by sequences capable of hybridizing thereto and coding for polypeptides with bone growth, factor biological properties or other variously modified sequences demonstrating such properties. One of the proteins of the invention is designated BMP- I. A portion of the human BMP-1 or hBMP-1 is characterized by the same or substantially the same peptide sequence as that of amino acid #1 through amino acid #37 of Table V, below which represents a genomic hBMP-1 fragment or amino acid #1 through amino acid #730 of Table VI which represents the : hBMP-1 cDNA. hBMP-1 or a related bone inductive factor may be further characterized by at least a portion of these sequences. These peptide sequences are encoded by the same or: substantially the same DNA sequence, as depicted in nucleotide #3440 through nucleotide #3550 of Table V and in nucleotide #36 through nucleotide #2225 of Table VI, respectively. These h.BMP-1 polypeptides are further characterized by the ability to induce bone formation. hBMP- 1 demonstrates activity in an in vivo rat bone formation assay at a concentration of 10 to lOOOng/gram of bone. The homologous bovine growth factor of the invention, designated bBMP-1, is characterized by a peptide sequence containing the same or substantially the same sequence as that of amino acid #1 through amino acid #37 of Table II below which represents a genomic bBMP-1 fragment. This peptide sequence is encoded by the same or substantially the same " DNA sequence as depicted in nucleotide #294 through nucleotide #404 of Table II. The bovine peptide sequence identified in Table II below is also 37 amino acids in length. bBMP-1 is further characterized by the ability to induce bone formation. Anotherbone inductiveprotein composition of the invention is designated BMP-2 Class I (or BMP-2) . It is characterized by at least a portion of a peptide sequence the same or substantially the same as that of amino acid #1 through amino acid #396 of Table VII which represents the cDNA hBMP-2 Class I. This peptide sequence is encoded by the same or substantially the same DNA sequence, as depicted in nucleotide #356 through nucleotide #1543 of Table VII. The human peptide sequence identified in Table VII is 396 amino acids in length. hBMP ' -2 or related bone inductive proteins may also be characterized by at least a portion of this peptide sequence. hBMP-2 Class I is further characterized by the ability to induce bone formation. The homologous bovine bone inductive protein of the invention designated bBMP-2 Class I (or bBMP-2) , has a DNA sequence identified in Table III below which represents the genomic sequence. This bovine DNA sequence has a prospective 129 amino acid' coding sequence followed by approximately 205 nucleotides (a presumptive 3 1 non-coding sequence). bBMP-2, Class I is further characterized by the ability to induce bone formation. Afurtherbone inductiveproteincomposition of the invention is designated BMP-2 Class II or BMP-4. The human protein hBMP-2 Class II (or hBMP-4) is characterized by at least a portion of the same or substantially the same peptide sequence between amino acid #1 through amino acid #408 of Table VIII, which represents the cDNA of hBMP-2 Class II. This peptide sequence is encoded by at least a portion of the same or substantially the same DNA sequence as depicted in nucleotide #403 through nucleotide #1626 of Table VIII. This factor is further characterized by the ability to induce bone formation. Still another bone inductive factor of the invention, BMP-3, is represented by the bovine homolog bBMP-3. bBMP-3 is characterized by the DNA sequence and amino acid sequence of Table IV A and' B which represents the bovine genomic sequence. It is characterized by at least a portion of a peptide sequence the same or substantially the same as amino acid #1 through amino acid #175 of Table IV A and B. BMP-3 is further characterized by the ability to induce bone formation. The bovine factor may be employed as a tool for obtaining the analogous human BMP-3 protein or other mammalian bone inductive proteins. The proper characterization of this bovine bone inductive factor provides the essential "starting point" for the. method employing this sequence. The method, employing techniques known to those skilled in the art of genetic engineering, involves using the bovine DNA sequence as a probe to screen a human genomic or cDNA library; and identifying the DNA sequences which hybridize to the probes. A clone with a hybridizable sequence is plaque purified and the DNA isolated therefrom, subcloned and subjected to DNA sequence analysis. Thus as another aspect of this invention is a human protein hBMF-3, produced by this method. Another aspect of the invention provides pharmaceutical compositions containing a therapeutically effective amount of one. or more bone growth factor polypeptides according to the invention in a pharmaceutically acceptable vehicle. These compositions may further include other therapeutically useful agents. They may also include an appropriate matrix for delivering the proteins to the site of the bone defect and for ' providing a structure for bone growth. These compositions may be employed in methods for treating a number of bone defects and periodontal disease. These methods, according to the invention, entail administering to a patient needing such bone formation an effective amount of at least one of the novel proteins BMP-1, BMP-2 Class I, BMP-2 Class-II, and BMP-3 as described herein. Still a further aspect of the invention are DNA sequences coding on expression for a human or bovine polypeptide having the ability to induce bone formation. Such sequences include the sequence of nucleotides in a 5' to 3 * direction illustrated in Tables II through VIII. Alternatively, a DNA sequence which hybridizes under stringent conditions with the DNA sequences of Tables II - VIII or a DNA sequence which hybridizes under non-stringent conditions with the illustrated DNA sequences and which codes on expression for a protein having at least one bone growth factor biological property are included in the present invention. Finally, allelic or other variations of the sequences of Tables II through VIII, whether such nucleotide changes result in changes in the peptide sequence or not, are also included in the present invention. Still a further aspect of the invention is a vector containing a DNA sequence as described above in operative association with an expression control sequence. Such vector may be employed in a novel process for producing a bone growth factor polypeptide in which a cell line transformed with a DNA sequence encoding expression of a bone growth factor polypeptide in operative association with an expression control sequence therefor, is cultured. This claimed process may employ a number of known cells as host cells for expression of the polypeptide. Presently preferred cell lines are mammalian cell lines and bacterial cells. Other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description and preferred ' embodiments thereof. Detailed Description of the Invention The proteins of the present invention are characterized by amino acid sequences or portions thereof the same as or substantially homologous to the sequences shown in Tables II - VIII below. These proteins are also characterized by the ability to induce bone formation. The bone growth factors provided herein also include factors encoded by the sequences similar to those of Tables II - VIII, but into which modifications are naturally provided (e.g. allelic variations in the nucleotide sequence which may result in amino acid changes in the polypeptide) or deliberately engineered. For example, synthetic polypeptides may wholly or partially duplicate continuous sequences of the amino acid residues of Tables II - VIII. These sequences, by virtue of sharing primary, secondary, or tertiary structural and conformational characteristics with bone growth factor polypeptides of Tables II - VIII may possess bone growth factor biological properties in common therewith. Thus, they may be empljoyed as biologically active substitutes for naturally- occurring bone growth factor polypeptides in therapeutic processes. Other specific mutations of the sequences of the bone growth" factors described herein involve modifications of one or both of the glycosylation sites. The absence of glycosylation or only partial glycosylation results from amino acid, substitution or deletion at one or both of the asparagine—Linked glycosylation recognition sites present in the -sequences of the bone growth factors shown in Tables II- VIIX " . The asparagine-linked glycosylation recognition sites comprise tripeptide sequences which are specifically recognized by appropriate cellular glycosylation enzymes. Thesetripeptide sequences, are either asparagine-X-threonine or asparagine-X- serine, where X is usually any amino acid. A variety of amino acid substitutions or deletions at one or both of the first or third amino acid positions of a glycosylation recognition site (and/or amino acid deletion at the second position) results in non-glycosylation at the modified tripeptide sequence. The present invention also encompasses the novel DNA sequences, free of association with DNA sequences encoding other proteinaceous materials, and coding on expression for bone growth factors. These DNA sequences include those depicted in Tables II - VIII in a 5• to 3' direction and those sequences which.hybridize under stringent hybridization conditions [see, T. Maniatis et al. Molecular Cloninσ (A Laboratory Manual) , Cold„Spring Harbor Laboratory (1982) , pages 387 to 389] to the DNA sequences of Tables II - VIII. DNA sequences which hybridize to the sequences of Tables II --VIII under relaxed hybridization conditions and which code on expression for bone growth factors having bone growth factor biological properties also encode bone growth factors of the invention. For example, a DNA sequence which shares regions of significant homology, e.g., sites of glycosylation or disulfide linkages, with the sequences of Tables II - VIII and encodes a bone growth factor having one or more bone growth factor biological properties clearly encodes a member of this novel family of growth factors, even if such a DNA sequence would not stringently hybridize to the sequence of Tables II - VIII. Similarly, DNA sequences which code for bone growth factor polypeptides coded for by the sequences of Tables II - VIII, but which differ in codon sequence due to the degeneracies of the genetic code or alleliσ variations (naturally-occurringbase changes in the species population which may or may not result in- an amino acid change) also encode the novel growth factors described herein. Variations in the DNA sequences of Tables II -VIII which are caused by point mutations or by induced modifications to enhance the activity, half-life or production of the polypeptides encoded thereby are also encompassed in the invention. Another aspect of the present invention provides a novel method for producing the novel osteoinductive factors. The method of the present invention involves culturing a suitable cell or cell line, which has been transformed with a DNA sequence coding on expression for a novel bone growth factor polypeptide of the invention, under the control of known regulatory sequences. Suitable cells or cell lines may be mammalian cells, such as Chinese hamster ovary cells (CHO) . The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature . 293 ; 620-625 (1981) , or alternatively, Kaufman et al, Mol. Cell. Biol. , 5.(7) :1750-1759 (1985) or Howley et al, U.S. Patent 4,419,446. Another suitable mammalian cell line, which is described in the accompanying examples, is the monkey COS-1 cell line. A similarly useful mammalian cell line is the CV-1 cell line. Bacterial cells are suitable hosts. For example, the various strains of E. coli (e.g., HB101, MC1061) are well-known as host cells* in the field of biotechnology. Various strains of B - subtilis, Pseudomonas. other bacilli and the like may also be employed in this method. Many strains of yeast cells known to those skilled in the art", are also available as host cells for expression of the polypeptides of the present invention. Additionally, where desired, insect cells may be utilized as host cells in the method of the. present invention. See, e.g. Miller et al, Ggnetic Errcrxneerinq, 8.:277-298 (Plenum Press 1986) and references cited therein. Another, aspect of the present invention provides vectors for- use in * the method of expression of these novel osteoinduct ve- polypeptides. Preferably the vectors contain the full novel DNA sequences described above which code for the novel " factors of the invention. Additionally the vectors also contain appropriate expression control sequences permitting expression of the bone inductive protein sequences. Alternatively, vectors incorporating modified sequences as described above- are also embodiments of the present invention and useful in the production of the bone inductive proteins. The vectors may be employed in the method of transforming cell llines and' contain selected regulatory sequences in operative association with the DNA coding sequences of the invention which are capable of directing the replication and expression thereof in selected host cells. Useful regulatory sequences for such vectors are known to one of skill in the art and may be selected depending upon the selected host cells. Such selection is routine and does not form part of the present invention. A protein of the present invention, which induces bone growth,in circumstances where bone is not normally formed, has application in the healing of bone fractures. An osteogenic preparation employing one or more of the proteins of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery. An osteogenic factor of the invention may be valuable in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. Of .course, the proteins of the invention may have other therapeutic uses. A further aspect of the invention is a therapeutic method and composition for repairing fractures and other conditions related to bone defects or periodontal diseases. Such a composition comprises a therapeutically effective amount of at least one of the bone inductive factor proteins of the invention. The bone inductive factors according to the present invention may be present in a therapeutic composition in • admixture with a pharmaceutically acceptable vehicle or matrix. Further therapeutic methods and compositions of the invention comprise a therapeutic amount of a bone inductive factor of the invention with a therapeutic amount of at least one of the other bone inductive factors of the invention. Additionally, the proteins according to the present invention or a combination of the proteins of the present invention may be co-administered with one or more different osteoinductive factors with which it may interact. Further, the bone inductive proteins may be combined with other agents beneficial to the treatment of the bone defect in question. Such agents include, but are not limited to various growth factors. The preparation of such physiologically acceptable protein compositions, having due regard to pH, isotonicity, stability and the like, is within the skill of the art. In particular, BMP-1 may be used individually in a composition. BMP-1 may also be used in combination with one or more of the other proteins of the invention. BMP-1 and. BMP-2 Class I may be used in combination. BMP-1 and BMP- 2 Class II may also be used in combination. BMP-1 and BMP-3 may be used in combination. Furthermore, BMP-1 may be used in combination with two or three of the other proteins of the invention. For example, BMP-1, BMP-2 Class I, and BMP-2 Class II may be combined. BMP-1 may also be combined with BMP—2 Class I, and BMP-3. Further, BMP-1 may be combined witx BMP-2 Class II, and BMP-3. BMP-1, BMP-2 Class I, BMP-2 Class II, and BMP-3 may be combined. BMP-2 Class I may be used individually in a pharmaceutical composition. BMP-2 Class I may also be used in combination with one or more of the other proteins of the invention. BMP-2 Class I may be combined with BMP-2 Class II. It may also be combined with BMP-3. Further BMP-2 Class I may be combined with BMP-2 Class II and BMP-3. BMP-2 Class II may be used individually in pharmaceutical composition. In addition, it may be used in combination with other proteins as identified above. Further it may be used in combination with BMP-3. BMP-3 may be used individually in a composition. It may further be used in the various combinations identified above. The therapeutic method includes locally administering the composition as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone damage. Preferably, the bone growth inductive factor composition would include a matrix capable of delivering the bone inductive factor to the site of bone damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of other materials presently in use for other implanted medical applications. The choice of material is based on, for example, bioσompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. Similarly, the application of the osteoinductive factors will define the appropriate formulation. Potential matrices for the osteoinductive factors may be biodegradable and chemically defined,, such as, but not limited to calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyanhydrides; biodegradable and biologically well defined, such as 1 bone or dermal collagen, other pure proteins or extracellularmatrixcomponents; nonbiodegradable andchemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics; or combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics might also be altered in composition, such as in calcium-aluminate- phosphate and processing to- alter for example, pore size, particle size, particle shape, and biodegradability. The dosage regimen will be determined by the attending physician considering various factors which modify the action of such a growth factor, e.g. amount of bone weight desired to be formed, the site of bone damage, the condition of the damaged bone, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and the composition of BMP's. The addition of other known growth factors, such as IGF 1 (insulin like growth factor 1) , to the final composition, may also effect the dosage. Generally, the dosage regimen should be in the range of approximately 10 to 10 6 nanograms of protein per gram of bone weight desired. Progress can be monitored by periodic assessment of bone growth and/or repair, e.g. x-rays. Such therapeutic compositions are also presently valuable for veterinary applications due to the lack of species specificity in bone inductive factors. Particularly domestic animals and thoroughbred horses in addition to humans are desired patients for such treatment with the bone inductive factors of the present invention. The following examples illustrate practice of the present invention in recovering and characterizing the bovine proteins and employing them to recover the human proteins, obtaining the human proteins and in expressing the proteins via recombinant techniques. EXAMPLE I Isolation of Bovine Bone Inductive Factor Ground bovine bone powder (20-120 mesh, Helitrex) is prepared according to the procedures of M. R. Urist et al., Proc. Natl Acad. Sci USA. 70:3511 (1973) with elimination of some extraction steps as identified below. Ten kgs of the ground powder is demineralized in successive changes of 0.6N HC1 at 4°C over a 48 hour period with vigorous stirring. The resulting suspension is extracted for 16 hours at 4°C with 50 liters of 2M CaCl 2 and lOmM ethylenediamine-tetraacetiσ acid CEDTA] . and followed by extraction for 4 hours in 50 liters of 0.5M EDTA. The residue is washed three times with distilled water before its resuspension in 20 liters of 4M guanidine hydrochloride [GuCl] , 20mM Tris (pH7.4), ImM N-ethylmaleimide, ImM iodoacetamide, ImM phenylmethylsulfonyl - fluorine as described in Clin. Orthop. Rel. Res.. 171: 213 (1982) . After 16 to 20 hours the supernatant is removed and replaced with another 10 liters of GuCl buffer. The residue is extracted for another 24 hours. The crude GuCl extracts are combined, concentrated approximately 20 times on a Pellicon apparatus with a 10,000 molecular weight cut-off membrane, and then dialyzed in 50mM Tris, 0.1M NaCl, 6M urea (pH7.2), the starting buffer for the first column. After extensive dialysis the protein is loaded on a 4 liter DEAE cellulose column and the unbound fractions are collected. The unbound fractions are concentrated and dialyzed against 50mM NaAc, 50mM NaCl (pH 4.6) in 6M urea. The unbound fractions are applied to a carboxymethyl cellulose column. Protein not bound to the column is removed by extensive washing with starting buffer, and the bone inductive factor containing material desorbed from the column by 50mM NaAc, 0.25mM NaCl, 6M urea (pH 4.6). The protein from this step elution is con¬ centrated 20- to 40- fold, then diluted 5 times with 80mM KPO4, 6M urea (pH6.0). The pH of the solution is adjusted to 6.0 with 500mM K 2 HP0 4 . The sample is applied to an hydroxylapatite column (LKB) equilibrated in 80mM KP0 4 , 6M urea (pH6.0) and all unbound protein is removed by washing the column with the same buffer. Bone inductive factor activity is eluted with lOOmM KP0 4 (pH7.4) and 6M urea. The protein is concentrated approximately 10 times, and solid NaCl added to a final concentration of 0.15M. This material is applied to a heparin - Sepharose column equilibrated in 50mM KPO4, 150mM NaCl, 6M urea (pH7.4). After extensive washing of the column with starting buffer, a protein with bone inductive factor activity is eluted by 50mM KP0 , 700mM NaCl, 6M urea (pH7.4). This fraction is concentrated to a minimum volume, and 0.4ml aliquots are applied to Superose 6 and Superose 12 columns connected in series, equilibrated with 4M GuCl, 20mM Tris (pH7.2) and the columns developed at a flow rate of 0.25ml/min. The protein demonstrating bone inductive factor activity has a relative migration corresponding to approximately 30,000 dalton protein. The above fractions are pooled, dialyzed against 50mM NaAc, 6M urea (pH4.6), and applied to a Pharmacia MonoS HR column. The column is developed with a gradient to l.OM NaCl, 50mM NaAc, 6M urea (pH4.6) . Active fractions are pooled and brought to pH3.0 with 10% trifluoroacetic acid (TFA) . The material is applied to a 0.46 x 25cm Vydaσ C4 column in 0.1% TFA and the column developed with a gradient to 90% acetonitrile, 0.1% TFA (31.5% acetonitrile, 0.1% TFA to 49.5% acetonitrile, 0.1% TFA in 60 minutes at 1ml per minute) . Active material is eluted at-approximately 40-44% acetonitrile. Aliquots of the appro¬ priate fractions are iodinated by one of the following methods: P. σ. McConahey et al. Int. Arch. Allergy. 29:185-189 (1966); A. E. Bolton et al, Biochem J.. 133:529 (1973); and D. F. Bowen-Pope, J. Biol. Chem.. 237:5161 (1982) . The iodinated proteins present in these fractions are analyzed by SDS gel electrophoresis and urea Triton X 100 isoelectric focusing. A -this stage, the bone inductive factor is estimated to be approximately 10-50% pure. EXAMPLE II Characterization of Bovine Bone Inductive Factor A. Molecular Weight Approximately 20ug protein from Example I is lyophilized and redissolved in " IX SDS sample buffer. After 15 minutes of heating at 37°C, the sample is applied to a 15% SDS polyacrylamide gel and then electrophoresed with cooling. The molecular weight is determined relative to prestained molecular weight standards (Bethesda Research Labs) . Immediately after completion, the gel lane containing bone inductive factor is sliced into 0.3cm pieces. Each piece is mashed and 1.4ml of 0.1% SDS is added. The samples are shaken gently overnight at room temperature to elute the protein. Each gel slice is desalted to prevent interference in the biological assay. The supernatant from each sample is acidified to pH 3.0 with 10% TFA, filtered through a 0.45 micron membrane and loaded on a 0.46cm x 5cm C4 Vydac column developed with a gradient of 0.1% TFA to 0.1% TFA, 90% CH 3 CN. The appropriate bone inductive factor - containing fractions are pooled and reconstituted with 20mg rat matrix. In this gel system, the majority of bone inductive factor fractions have the mobility of a protein having a molecular weight of approximately 28,000 - 30,000 daltons. B. Isoelectric Focusing The isoelectric point of bone inductive factor activity is determined in a denaturing isoelectric focusing system. The Triton X100 urea gel system (Hoeffer Scientific) is modified as follows: 1) 40% of the ampholytes used are Servalyte 3/10; 60% are Servalyte 7-9. 2) The catholyte used is 40mM NaOH. Approximately 20ug of protein from Example I is lyophilized, dissolved in sample buffer and applied to the isoelectrofocusing gel. The gel is run at 20 watts, 10°C for approximately 3 hours. At completion the lane containing bone inductive factor is sliced into 0.5 cm slices. Each piece is mashed in 1.0ml 6M urea, 5mM Tris (pH 7.8) and the samples agitated at room temperature. The samples are acidified, filtered, desalted and assayed as described above. The major portion of activity as determined in the assay described in Example III migrates in a manner consistent with a pi of 8.8 - 9.2. C. Subunit Characterization The subunit composition of bone inductive factor is also determined. Pure bone inductive factor is isolated from a preparative 15% SDS gel as described above. A portion of the sample is then reduced with 5mM DTT in sample buffer and re-electrophoresed on a 15% SDS gel. The approximately 30kd protein yields two major bands at approximately 20kd and 18kd, as well as a minor band at 30kd. The broadness of the two bands indicates heterogeneity caused most probably by glycosylation, other post translational modification, proteolytic degradation or carbamylation. EXAMPLE III Biological Activity of Bone Inductive Factor A rat bone formation assay according to the general procedure of Sampath and Reddi, Proc. Natl. Acad. Sci. U.S.A.. 80:6591-6595 (1983) is used to evaluate the osteogenic activity of the bovine- bone inductive factor of the present invention obtained in Example T, This assay can also be used to evaluate bone- 8 inductive factors of other species. The ethanol precipitation step is replaced by dialyzing the fraction to be assayed against water. The solution or suspension is then redissolved in. a volatile solvent, e.g. 0.1 - 0.2 % TFA, and the resulting- solution added to 20mg of rat matrix. This material is. frozen and lyophilized and the resulting powder enclosed in- #5; gelatin capsules. The capsules are implanted subcutaneously in the abdominal thoracic area of 21 - 49 day old male long- Evans rats. The implants are removed after 7 - 14 days. Half, of each, implant is used for alkaline phosphatase analysis [See, A. H. Reddi et al., Proc. Natl Acad Sci. , 69:1601 (1972) ] and half is fixed and processed for histological analysis. Routinely, lum glycolmethacrylate sections are stained with Von Kossa and acid fuschin to detect new bone mineral. Alkaline phosphatase, an enzyme produced by chondroblasts and osteoblasts in the process of matrix formation, is- also measured. New cartilage and bone formation often correlates with alkaline phosphatase levels. Table I below illustrates the dose response of the rat matrix samples including a control not treated with bone inductive factor. TABLE 1 Protein* Implanted ucr Cartilage Alk. Phos.u/1 7.5 2 Not done 2.5 3 445.7 0.83 3 77.4 0.28 0 32.5 0.00 0 31.0 *At this stage the bone inductive factor is approximately 10-15% pure. The bone or cartilage formed is physically confined to the space occupied by the matrix. Samples are also analyzed by SDS gel electrophoresis and isoelectric focusing as described above, followed by autoradiography. Analysis reveals a correlation of activity with protein bands at 28 - 30kd and a pi 9.0. An extinction coefficient of 1 OD/mg-cm is used as an estimate for protein and approximating the purity of bone inductive factor in a particular fraction. In the in vivo rat bone formation assays on dilutions as described above, the protein is active in vivo at 10 to 200ng protein/gram bone to probably greater than lug protein/gram bone. EXAMPLE IV Bovine Bone Inductive Factor Protein Composition The protein composition of Example IIA of molecular weight 28 - 30kd is reduced as described in Example IIC and digested with trypsin. Eight tryptic fragments are isolated by standard procedures having the following amino acid sequences: Fragment 1 A A F L G D I A L D E E D L G Fragment 2 A F Q V Q Q A A D L Fragment 3 N Y Q D M V V E G Fragment 4 S T P A Q D V S R Fragment 5 N Q E A L R Fragment 6 L S E P D P S H T L E E Fragment 7 F D A Y Y Fragment 8 L K P S N 7 A T I Q S I V E A less highly purified preparation of protein from bovine bone is prepared according to a purification scheme similar to that described in Example I. The purification basically varies from that previously described by omission of the DE-52 column, the CM cellulose column and the mono S column, as well as a reversal in the order of the hydroxylapatite and heparin sepharose columns. Briefly, the concentrted crude 4 M extract is brought to 85% final concentration of ethanol at 4 degrees. The mixture is then centrifuged, and the precipitate redissolved in 50 M Tris, 0.15 M NaCl, 6.0 M urea. This material is then fractionated on Heparin Sepharose as described. The Heparin bound material is fractionated on hydroxyapatite as described. The active fractions are pooled, concentrated, and fractionated on a high; resolution gel filtration (TSK 30000 in 6 M guanidinium chloride, 50 mM Tris, pH 7.2). The active fractions are pooled, dialyzed against 0.1% TFA, and then fractionated on a C4 Vydac reverse phase column as described. The preparation is reduced and electrophoresed on an acrylamide gel. The protein corresponding to the 18K band is eluted and digested with trypsin. Tryptic fragments are isolated having the following amino acid sequences: Fragment 9: S L K P S N H A T I Q S 7 V Fragment 10: S F D A Y Y C S 7 A Fragment 11: V Y P N M T V E S C A Fragment 12: V D F A D I 7 W Tryptic Fragments 7 and 8 are noted to be substantially the same as Fragments 10 and 9, respectively. A. bBMP-1 Probes consisting of pools of oligonucleotides (or unique oligonucleotides) are designed according to the method of R. Lathe, J. Mol. Biol. , 183 (1):1-12 (1985) and synthesized on an. automated DNA synthesizer. One probe consists of a relatively long (32 nucleotides) "guessmer" [See J. J. Toole et al. Nature. 312:342-347 (1984)] of the following nucleotide sequence: TCCTCATCCAGGGCAATGTCGCCCAGGAAGGC Because the genetic code is degenerate (more than one codon can code for the same amino acid) , the number of oligo¬ nucleotides in a probe pool is reduced based on the frequency of codon usage in eukaryotes, the relative stability of G:T base pairs, and the relative infrequency of the dinucleotide CpG in eukaryotic coding sequences [see Toole et al., supra.]. The second set of probes consists of shorter oligonucleotides (17 nucleotides in length) which contain all possible sequences that could encode the amino acids. The second set of probes has the following sequences: (a) A [A/G] [A/G] TC [T/C] TC [T/C] TC [A/G] TC [T/C] AA (b) A [A/G] [A/G] TC [T/C] TC [T/C] TC [A/G] TCNAG Bracketed nucleotides are alternatives. "N" means either A, T, C or G. In both cases the regions of the amino acid sequence used for probe design are chosen by avoiding highly degenerate codons where possible. The oligonucleotides are synthesized on an automated DNA synthesizer; the probes are then radio- actively labeled with polynucϊeotide kinase and 32 P-ATP. These two sets of probes are used to screen a bovine genomic recombinant library. The library is constructed as follows: Bovine liver DNA is partially digested with the restriction endonuclease enzyme Sau 3A and sedimented through a sucrose gradient. Size fractionated DNA in the range of 15-3Okb is then ligated to the bacteriophage Bam HI vector EMBL3 [Frischauf et al, J. Mol. Biol.. 170:827-842 (1983)]. The library is plated at 8000 recombinants per plate. Duplicate nitrocellulose replicas of the plaques are made and amplified according to a modification of the procedure of Woo et al, Proc. Natl. Acad. Sci. USA. 75:3688-91 (1978) . The 32 er probe is kinased with 32 P-gamma-ATP and hybridized to one set of filters in 5X SSC, 0.1% SDS, 5X Denhardts, lOOug/ml salmon sperm DNA at 45 degrees C and washed with 5X SSC, 0.1% SDS at 45 degrees C. The 17 mer probes are kinased and hybridized to the other set of filters in 3M tetramethyla monium chloride (TMAC) , 0.1M sodium phosphate pH6.5, ImM EDTA, 5X Denhardts, 0.6% SDS, lOOug/ml salmon sperm DNA at 48 degrees C, and washed in 3M TMAC, 50mM Tris pH8.0 at 50 degrees C. These conditions minimize the detection of mismatches to the 17 mer probe pool [see, Wood et al, Proc. Natl. Acad. Sci. U.S.A.. 82:1585-1588 (1985) ] . 400,000 recombinants are screened by this procedure and one duplicate positive is plaque purified. DNA is isolated from a plate lysate of this recombinant bacteriophage designated lambda bP- 50. bP-50 was deposited December 16, 1986 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland USA (hereinafter the "ATCC") under accession number 40295. This deposit as well as the other deposits contained herein meets the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and Regulations thereunder. This bp-50 clone encodes at least a portion of the bovine bone growth factor designated bBMP-1. The=oligonucleotide hybridizing region of this bBMP-1 clone is -localized to an approximately 800bp Eco Rl fragment which is -subcloπed into M13 and sequenced by standard techniques. The partial DNA sequence and derived amino acid sequence of lambda bP-50 are shown below in Table II. The amino acid sequences corresponding to the tryptic fragments isolated from the bovine bone 28 to 30kd material are underlined in Table II. The first underlined portion of the sequence c rresponds to ^ tryptic Fragment 1 above from which the oligonucleotide probes are designed. The second underlined portion corresponds to tryptic Fragment 2 above. The predicted amino acid sequence indicates that tryptic Fragment 2 is preceded by a basic residue (R) as expected considering the specificity σf trypsin. The nucleic acid sequence preceding the couplet CT at nucleotide positions #292-293 in Table II is presumed to be an intron (noncoding sequence) based on the presence of a consensus acceptor sequence (i.e., a pyri idine rich tract, TCTCTCTCC, followed by AG) and the lack of a basic residue in the appropriate position of the derived amino acid sequence. This bBMP-1 genomic sequence appears in Table II. The presumptive bBMP-1 peptide sequence from this genomic clone is 37 amino acids in length and is encoded by the DNA sequence from nucleotide #294 through #404 in Table II. TABLE II 280 290 • (1) 308 323 CC TGCCTCT TCTCTCTCCA GCT GCC TTC CTT GGG GAC ATC GCC CTG GAC GAG GAG Ala Phe Leu Glv Asp lie Ala Leu Asp Glu Glu 338 353 368 GAC TTG AGG GCC TTC CAA GTG CAG CAG GCT GCG GAC CTC AGA CAG CGT GCA ACC Asp Leu Arg Ala Phe Gin Val Gin Gin Ala Ala Asp Leu Arg Gin Arg Ala Thr 383. 398 (37) 414 424 CGC.AGG TCT TCC ATC AAA GCT GCA GGTACACTGG GTACAGGCCA Arg Arg Ser Ser lie Lys Ala Ala B. bBMP-2 Twσ probes consisting of pools of oligonucleotides are designed on the basis of the amino acid sequence of Fragment 3.and synthesized on an automated DNA synthesizer as described above. Probe #1: A C N A C C A T [A/G] T C [T/C] T G [A/G] A T Probe #2: C A [A/G] G A [T/C] A T G G T N G T N G A Thes s probes are radioactively labeled and employed to screen theabovin genomic library constructed as described in part A except that the vector is lambda Jl Bam HI arms [Mullins et al Nature 308: 856-858 (1984) .] The radioactively labelled 17-mer Probe #1 is hybridized to the set of filters according to the method for the 17 mer probe described in part A. 400,000 recombinants are screened by the procedure described above in Part A. One duplicate positive is plaque purified and the DNA is isolated from a plate lysate of the recombinant bacteriophage designated lambda bP-21.' Bacteriophage bP-21 was deposited with the ATCC under accession number ATCC 40310 on March 6, 1987. The bP-21 clone encodes the-bovine growth factor designated bBMP-2. The oligonucleotide hybridizing region ' of this bBMP-2 clone- isr localized to an approximately 1.2 kb Sac I restriction fragment which, is subcloned into M13 and sequenced by standard techniques. The partial DNA sequence and derived amino acid sequence of this Sac I fragment and the contiguous Hind III- Sac r restriction fragment of bP-21 are shown below in Table III. The bBMP-2 peptide sequence from this clone is 129 amino acids in length and is encoded by the DNA sequence from nucleotide #1 through nucleotide #387. The amino acid sequence corresponding to the tryptic fragment isolated from the bovine bone 28 to 30kd material is underlined in Table III. The underlined portion of the sequence corresponds to tryptic Fragment 3 above from which the oligonucleotide probes for bBMP-2 are designed. The predicted amino acid sequence indicates that tryptic Fragment 3 is preceded by a basic residue (K) as expected considering the specificity of trypsin. The arginine residue encoded by the CGT triplet is presumed to be the carboxy-terminus of the protein based on the presence of a stop codon (TAG) adjacent to it. TABLE III (1) 15 30 45 GGC CAC GAT GGG AAA GGA CAC CCT CTC CAC AGA AGA GAA AAG CGG G H D G K G H P L H R R E K R 60 75 90 CAA GCA AAA CAC AAA CAG CGG AAA CGC CTC AAG TCC AGC TGT AAG Q A K H K Q R K R L K S S C K 105 120 135 AGA CAC CCT TTA TAT GTG GAC TTC AGT GAT GTG GGG TGG AAT GAC R H P L Y V D F S D V G W N D 150 165 180 TGG ATC GTT GCA CCG CCG GGG TAT CAT GCC TTT TAC TGC CAT GGG W I V A P P G Y H A F Y C H G 195 210 225 GAG TGC CCT TTT CCC CTG GCC GAT CAC CTT AAC TCC ACG AAT CAT E C P F P L A D H L N S T N H 240 255 270 GCC ATT CTC CAA ACT CTG GTC AAC TCA GTT AAC TCT AAG ATT CCC A I V Q T L V N S V N S K I P 385 300 315 AAG GCA TGC TGT GTC CCA ACA GAG CTC AGC GCC ATC TCC ATG CTG K A C C V P T E L S A I S M L 330 345 360 TAC CTT GAT GAG AAT GAG AAG GTG GTA TTA AAG AAC TAT CAG GAC Y L D E N E K V V L K N Y 0 D 375 (129) 397 407 ATG GTT GTC GAG GGT TGT GGG TGT CGT TAGCACAGCA AAATAAAATA M V V E G C G C R 417 427 437 447 457 TAAATATATA TATATATATA TTAGAAAAAC AGCAAAAAAA TCAAGTTGAC 467 477 487 497 507 ACTTTAATAT TTCCCAATGA AGACTTTATT TATGGAATGG AATGGAGAAA 517 527 537 547 557 AAGAAAAACA CAGCTATTTT GAAAACTATA TTTATATCTA CCGAAAAGAA 567 577 587 GTTGGGAAAA CAAATATTTT AATCAGAGAA TTATT C. bBMP-3 Probes consisting of pools of oligonucleotides are designed on the basis of the amino acid sequences of the tryptic Fragments 9 (Probe #3), 10 (Probe #2), and 11 (Probe #1) , and synthesized on an automated DNA synthesizer. Probe #1: A C N G T C A T [A/G] T T N G G [A/G] T A Probe #2: C A [A/G] T A [A/G] T A N G C [A/G] T C [A/G] A A Probe- #3: T: G [A/G/T] A T N G T N G C [A/G] T G [A/G] T T A recombinant bovine genomic library constructed in EMBL3 is screened by the TMAC hybridization procedure detailed above in part A. 400,000 recombinants are screened in duplicate with Probe #1 which has been labeled with 32 P. All recombinants which hybridized to this probe are replated for secondaries. Triplicate nitrocellulose replicas -are made of the secondary plates, and amplified as described. The three sets of filters are hybridized to Probes #1, #2 and #3, again under TMAC conditions. One clone, lambda bP-819, hybridizes to all three probes and is plaque purified and DNA is isolated from a plate lysate. Bacteriophage lambda bP-819 was deposited with the ATCC on June 16, 1987 under accession number 40344. This bP-819 clone encodes the bovine bone growth factor designated bBMP-3. The region of bP-819 which hybridizes to Probe #2 is localized and sequenced. The partial DNA and derived amino acid sequences of this region are shown in Table IVA. The amino acid sequences corresponding to tryptic Fragments 10 and 12 are underlined. The first underlined sequence corresponds to Fragment 12 while the second corresponds to Fragment 10. This region of bP-819, therefore, which hybridizes to Probe #2 encodes at least 111 amino acids. This amino acid sequence is encoded by the DNA sequence from nucleotide #414 through #746. TABLE IV. A. 383 393 403 413 (1) 428 GAGGAGGAAG OSΞECTACGG GGGTCCTTCT GCCTCTGCAG AAC AAT GAG CTT CCT GGG GCA Asn Asn Glu Leu Pro Gly Ala 443 458 473 488 GAA TAT CAG TAC AAG GAG GAT GAA GTA TGG GAG GAG AGG AAG CCT TAC AAG ACT Glu Tyr Gin Tyr Lys Glu Asp Glu Val Trp Glu Glu Arg Lys Pro Tyr Lys Thr 503 518 533 CTT CAG ACT CAG CCC CCT GAT AAG AGT AAG AAC AAA AAG AAA CAG AGG AAG GGA Leu Gin Thr Gin Pro Pro Asp Lys Ser Lys Asn Lys Lys Lys Gin Arg Lys Gly 548 563 578 593 CCT CAG CAG AAG ACT CAG ACG CTC CAG TTT GAT GAA CAG ACC CTG AAG AAG GCA Pro Gin Gin Lys Ser Gin Thr Leu Gin Phe Asp Glu Gin Thr Leu Lys Lys Ala 608 623 638 AGA AGA AAG CAA TGG ATT GAA CCC CGG AAT TGT GCC AGA CGG TAC CTT AAA GTG Arg Arg Lys Gin Trp lie Glu Pro Arg Asn Cys Ala Arg Arg Tyr Leu Lys Val 653 668 683 698 GAC TTC GCA GAT ATT GGC TGG AGC GAA TGG ATT ATT TCC CCC AAG TCC TTC GAT Asp Phe Ala Asp lie Gly Trp Ser Glu Trp lie lie Ser Pro Lys Ser Phe ASP 713 728 743 (111) 756 GCC TAT TAC TGC TCC GGA GOG TGC CAG TTC CCC ATG CCA AAG GTAGCCATTG Ala Tyr Tyr Cys Ser Gly Ala Cys Gin Phe Pro MET Pro Lys 766 776 786 TIT'ILL'IGTCC TGTCCTTCCC ATTICCATAG The region of bP-819 which hybridizes to Probe #1 and #3 is localized and sequenced. The partial DNA and derived amino acid sequences of this region are shown in Table IVB. The amino acid sequences corresponding to tryptic Fragments 9 and 11 are underlined. The first underlined sequence corresponds to Fragment 9 while the second underlined sequence corresponds to Fragment 11. The peptide sequence of this region of bP-819 which hybridizes to Probe #1 and #3 is 64 amino acids in length encoded by nucleotide #305 through #493 of Table IVB. The arginine residue encoded by the AGA triplet is presumed to be the carboxy-terminus of the protein based on the presence of a stop codon (TAA) adjacent to it. The nucleic acid sequence preceding the couplet TC (positions 305-306) is presumed to be an intron (non-coding sequence) based on the presence of a consensus acceptor sequence (i.e. a pyrimidine-rich stretch, TTCTCCCTTTTCGTTCCT, followed by AG) and the presence of a stop rather than a basic residue in the appropriate position of the derived amino acid sequence. bBMP-3 is therefore characterized by the DNA and amino acid sequence of Table IV A and Table IV B. The peptide sequence of this clone is 175 amino acids in length and is encoded by the DNA sequence from nucleotide #414 through nucleotide #746 of Table IV A and nucleotide #305 through nucleotide #493 of Table IV B. TABLE IV. B . 284 294 304 (112) 319 CTAACCTGTG TTCTCOCTTr TCGTTCCTAG TCT TTG AAG CCA TCA AAT CAC GCT ACC Ser Leu Lys Pro Ser Asn His Ala Thr 334 349 364 379 ATC CAG ACT ATA CTG AGA GCT GTG GGG CTC CTC CCT GGA ATC CCC GAG CCT TGC He Gin Ser He Val Arg Ala Val Gly Val Val Pro Gly lie Pro Glu Pro Cys 394 409 424 439 TGT GTG CCA GAA AAG ATG TCC TCA CTC AGC ATC TTA TTC TTT GAT GAA AAC AAG Cys Val Pro Glu Lys MET Ser Ser Leu Ser lie Leu Phe Phe Asp Glu Asn Lys 454 469 484 (175) AAT GTS GTA CTT AAA GTA TAT CCA AAC ATG ACA GTA GAG TCT TCT GCT TGC AGA Asn Val Val Leu Lys Val Tyr Pro Asn MET Thr Val Glu Ser Cys Ala " Cys Arg 503 513 523 533 TAACCTGGTG AAGAACTCAT CTGGATGCTT AACTCAATCG EXAMPLE V Human Bone Inductive Factors A. hBMP-1 Because the bovine and human bone growth factor genes are presumed to be significantly homologous, the bovine bBMP- 1 DNA sequence of Table II (or portions thereof) is used as a probe to screen a human ge.io ic library. The 800bp EcoRI fragment of the bovine genomic clone is labeled with 32 P by nick-translation. A human genomic library (Toole et al., supra) is plated on 20 plates at 40,000 recombinants per plate. Duplicate nitrocellulose filter replicas are made of each plate and hybridized to the nick-translated probe in 5 X SSC, 5 X Denhardt's, lOOug/ml denatured salmon sperm DNA, 0.1% SDS (the standard hybridization solution) at 50 degrees centigrade for approximately 14 hours. The filters are then washed in 1 X SSC, 0.1% SDS at 50 degrees centigrade and subjected' to autoradiography. Five duplicate positives are isolated and plaque purified. DNA is obtained from a plate lysate of one of these recombinant bacteriophage, designated LP-Hl. LP-Hl was deposited with the ATCC on March 6, 1987 under accession number 40311. This clone encodes at least a portion of the human genomic bone growth factor called hBMP-1. The hybridizing region of LP-Hl is localized to a 2.5kb Xbal/Hindlll restriction fragment. The partial DNA sequence and derived amino acid sequence of lambda LP-Hl are shown below in Table V. The peptide sequence from this clone is 37 amino acids in length and is encoded by the DNA sequence from nucleotide #3440 through nucleotide #3550. The coding sequence of Table V is flanked by approximately 28 nucleotides (a presumptive 5' noncoding sequence) as well as approximately 19 nucleotides (a presumptive 3 1 noncoding sequence. A comparison of the bBMP-1 sequence of Table II with the hBMP-1 genomic sequence of Table V indicates the significant homology between the two. Because the size of coding regions and the positions of noncoding regions is generally conserved in homologous genes of different species, the locations of the coding and noncoding regions of the bone inductive factor genes may be identified. Regions of homology between the two species' genes, flanked by RNA processing signals at homologous sites, indicate a coding region. TABLE V 3419 3429 3439 (1) 3454 CAGCCCTGGC TICTTCITTT CTCTITAGCT GCC TTT CTT GGG GAC ATT GCC CTG GAC Ala Phe Leu Gly Asp lie Ala Leu Asp 3469 3484 3499 3514 GAA GAG GAC CTG AGG GCC TTC CAG GTA CAG CAG GCT CTG GAT CTC AGA CGG CAC Glu Glu Asp Leu Arg Ala Phe Gin Val Gin Gin Ala Val Asp Leu Arg Arg His 3529 3544 (37) 3560 3570 ACA GCT CCT AAG TCC TCC ATC AAA GCT GCA GGTAAGCCGG GTGCCAATGG Thr.Ala Arg Lys Ser Ser He Lys Ala Ala A probe specific for the human coding sequence given in: Table V is used to identify a human cell line or tissue which- synthesizes bone inductive factor. The probe is made according to the following method. Two oligonucleotides having the following sequences: (a) GGGAATTCTGCCTTTCTTGGGGACATTGCCCTGGACGAAGAGGACCTGAG (b) CGGGATCCGTCTGAGATCCACAGCCTGCTGTACCTGGAAGGCCCTCAGG are^synthesized on an automated synthesizer, annealed, extended using- the Klenow fragment of E. coli DNA polymerase I, digested with:, the restriction enzymes Eco Rl and Bam HI, and inserted into an M13 vector. A single-stranded 32 P-labeled probe is then from template preparation of this subclone by standard techniques. Polyadenylated RNAs from various cell and tissue sources are electrophoresed on formaldehyde-agarose gels and transfered to nitrocellulose by the method of Toole et al., ' supra. The probe is then hybridized to the nitrocellulose blot in 50% formamide, 5 X SSC, 0.1% SDS, 40 mM sodium phosphate pH 6.5, 100 ug/ml denatured salmon sperm DNA, and 5 mM vanadyl ribonucleosides at 42° C overnight and washed at 65° C in 0.2 X SSC, 0.1% SDS. Following autoradiography, the lane containing RNA from the human psteosarcoma cell line U-2 OS contains hybridizing- bands corresponding to RNA species of approximately 4.3 and 3.0 kb. cDNA is synthesized from U-2 OS polyadenylated RNA and cloned into lambda gtlO by established techniques (Toole et al., supra). 20,000 recombinants from this library are plated on each of 50 plates. Duplicate nitrocellulose replicas are made of the plates. The above described oligonucleotides are kinased with 32 P-gamma-ATP and hybridized to the two sets of replicas at 55° centigrade in standard hybridization solution overnight. The filters are then washed in 1 X SSC, 0.1% SDS at 55° centigrade and subjected to autoradiography. One duplicate positive, designated lambda U20S-1, is plaque purified. Lambda U20S-1 was deposited with the ATCC on June 16, 1987 under accession number 40343. The entire nucleotide sequence and derived amino aci sequence of the insert of lambda U20S-1 is given in Table VI This cDNA clone encodes a Met followed by a hydrophobic leade sequence characteristic of a secreted protein, and contains stop codon at nucleotide positons 2226 - 2228. This clon contains an open reading frame of 2190bp, encoding a protein o 730 amino acids with a molecular weight og 83kd based on thi amino. acid sequence. The clone contains sequence identical t the coding region given in Table V. This protein is contemplate to;= represent a primary translation product which is cleave upon secretion to produce the hBMP-1 protein. This clone i therefore a cDNA for hBMP-1 corresponding to human gene fragmen contained in the genomic hBMP-1 sequence lambda LP-Hl. It i noted that amino acids #550 to #590 of BMP-1 are homologous t epidermal growth factor and the "growth factor" domains o Protein C, Factor X and Factor IX. TABLE VI 10 20 30 (1) 50 CTAGAGGCCG CITCCCTCGC CGCCGCCCCG CCAGC ATG CCC GGC GTG GCC CGC CTG CCG MET Pro Gly Val Ala Arg Leu Pro 65 80 95 110 CTG CTG CTC GGG CTG CTG CTG CTC CCG CCT CCC GGC CGG CCG CTG GAC TG GCC Leu Leu Leu Gly Leu Leu Lsu Leu Pro Arg Pro Gly Arg Pro Leu Asp Leu Ala 125 140 155 GAC " TAC ACC TAT GAC CTG GCG GAG GAG GAC GAC TCG GAG CCC CTC AAC TAC AAA Asp Tyr Thr Tyr Asp Leu Ala Glu Glu Asp Asp Ser Glu Pro Leu Asn Tyr Lys 170 185 200 215 GACTCCC TGC AAG GCG GCT GCC TTT CTT GGG GAC ATT GCC CTG GAC GAA GAG GAC Asp Pro Cys Lys Ala Ala Ala Phe Lsu Gly Asp lie Ala Leu Asp Glu Glu Asp 230 245 260 275 CTG AGG GCC TTC CAG GTA CAG CAG GCT GTG GAT CTC AGA CGG CAC ACA GCT CCT Leu Arg Ala Phe Gin Val Gin Gin Ala Val Asp Leu Arg Arg His Thr Ala Arg 290 305 320 AAG TCC TCC ATC AAA GCT GCA GTT CCA GGA AAC ACT TCT ACC CCC AGC TGC CAG ' Lys Ser Ser He Lys Ala Ala Val Pro Gly Asn Thr Ser Thr Pro Ser Cys Gin 335 350 365 380 AGC ACC AAC GGG CAG CCT CAG AGG GGA GCC TCT GGG AGA TGG AGA GCT AGA TCC Ser.Thr Asn Gly Gin Pro Gin Arg Gly Ala Cys Gly Arg Trp Arg Gly Arg Ser 395 410 425 CCT AGC CGG- CGG GCG GCG ACG TCC CGA CCA GAG CCT GIG TGG CCC GAT GGG GTC Arg Ser Arg Arg Ala Ala Thr Ser Arg Pro Glu Arg Val Trp Pro Asp Gly Val 440 455 470 485 ATC CCC TTT CTC ATT GGG GGA AAC TTC ACT GCT AGC CAG AGG GCA GTC TTC CGG He Pro Phe Val lie Gly Gly Asn Phe Thr Gly Ser Gin Arg Ala Val Phe Arg 500 515 530 545 CAG GCC ATG AGG CAC TGG GAG AAG CAC ACC TCT CTC ACC TTC CTG GAG CGC ACT Gin Ala MET Arg His Trp Glu Lys His Thr Cys Val Thr Phe Leu Glu Arg Thr 560 575 590 GAC GAG GAC AGC TAT ATT CTG TTC ACC TAT CGA CCT TGC GGG TGC TGC TCC TAC Asp Glu Asp Ser Tyr He Val Phe Thr Tyr Arg Pro Cys Gly Cys Cys Ser Tyr 605 620 635 650 GTG GCT CGC CGC GGC GGG GGC CCC CAG GCC ATC TCC ATC GGC AAG AAC TGT GAC Val Gly Arg Arg Gly Gly Gly Pro Gin Ala lie Ser He Gly Lys Asn Cys Asp 665 680 695 AAG TTC OKATT GTGGTC CAC GAG CTCGGC CAC CTO GTC Lys Phe Gly lie Val Val His Glu Lsu Gly His Val Val Gly Phe Trp His Glu 710 725 740 755 CAC ACT CGG CCA GAC CGG GAC CGC CAC CTT TCC ATC GTT CGT GAG AAC ATC CAG His Thr Arg Pro Asp Arg Asp Arg His Val Ser He Val Arg Glu Asn He Gin 770 785 800 815 CCA GGG CAG GAG TAT AAC TTC CTG AAG ATG GAG CCT CAG GAG CTG GAG TCC CTG Pro Gly Gin Glu Tyr Asn Phe Leu Lys MET Glu Pro Gin Glu Val Glu Ser Lu 830 845 860 GGG GAG ACCTAT GAC TTC GAC AGC ATC ATG CAT TAC GCT CGG AAC ACA TTC TCC Gly Glu Thr Tyr Asp Phe Asp Ser He MET His Tyr Ala Arg Asn Thr Phe Ser 875 890 905 920 AGG GGC ATC TTC CTG GAT ACC ATT GTC CCC AAG TAT GAG GTG AAC GGG GTG AAA Arg Gly He Phe Leu Asp Thr He Val Pro Lys Tyr Glu Val Asn Gly Val Lys 935 950 965 CCT CCC ATT GGC CAA AGG ACA CGG CTC AGC AAG GGG GAC ATT GCC CAA GCC CGC Pro Pro He Gly Gin Arg Thr Arg Leu Ser Lys Gly Asp He Ala Gin Ala Arg 980 995 1010 1025 AAG CTT TAC AAG TGC CCA GCC TCT GGA GAG ACC CTG CAA GAC AGC ACA GGC AAC Lys Leu Tyr Lys Cys Pro Ala Cys Gly Glu Thr Leu Gin Asp Ser Thr Gly Asn 1040 1055 1070 1085 TTC TCC TCC CCT GAA TAC CCC AAT GGC TAC TCT GCT CAC ATG CAC TGC CTG TGG Phe Ser Ser Pro Glu Tyr Pro Asn Gly Tyr Ser Ala His MET His Cys Val Trp 1100- 1115 1130 CGC ATC TCT GTC ACA CCC GGG GAGAAGATC ATC CT C TIC ACG TCC CTG GAC Arg He Ser Val Thr Pro Gly Glu Lys He lie Leu Asn Phe Thr Ser Leu Asp 1145 1160 1175 1190 CTG TAC CGC AGC OGC CTG TGC TGG AC GAC TAT GTG GAG GTC CGA GAT GGC TΓC Leu Tyr Arg Ser Arg- Leu Cys Trp Tyr Asp Tyr Val Glu Val Arg Asp Gly Phe 1205 1220 1235 TGG AGG AAG GCG CCC CTC OGA GGC CGC TTC TGC GGG TCC AAA CTC CCT GAG CCT Trp Arg Lys Ala Pro Leu Arg Gly Arg Phe Cys Gly Ser Lys Leu Pro Glu Pro 1250 1265 1280 1295 ATC GTC TCC ACT GAC AGC CGC CTC TGG GTT GAA TTC CGC AGC AGC AGC AAT TGG He Val Ser Thr Asp Ser Arg Leu Trp Val Glu Phe Arg Ser Ser Ser Asn Trp 1310 1325 1340 1355 C^PΓGGAAAGGGCTICTHGCAGI TACGAAGC ATCTGCC^ AAA Val Gly Lys Gly Phe Phe Ala Val Tyr Glu Ala He Cys Gly Gly Asp Val Lys 1370 1385 1400 AAG GAC ' TAT GGC CAC ATT CAA TOG CCC AAC TAC CCA GAC GAT TAC CGG CCC AGC Lys Asp-Tyr Gly His lie Gin Ser Pro Asn Tyr Pro Asp Asp Tyr Arg Pro Ser 1415 ' 1430 1445 1460 AAA CTC TGC ATC TGG CGG ATC CAG GTG TCT GAG GGC TTC CAC GTG GGC CTC ACA Lys Val Cys He Trp Arg He Gin Val Ser Glu Gly Phe His Val Gly Leu Thr 1475 1490 1505 TTC CAG TCC TTT GAG ATT GAG CGC CAC GAC AGC TCT GCC TAC GAC TAT CTG GAG Phe Gin Ser Phe Glu He Glu Arg His Asp Ser Cys Ala Tyr Asp Tyr Lsu Glu 1520- 1535 1550 1565 CTG CGCTGACGGG CAC ACT GAG AGC AGC ACC CTC ATC GGG CGC TAC TCT GGC TAT Val-Arg Asp Gly His Ser Glu Ser Ser Thr Leu He Gly Arg Tyr Cys Gly Tyr 1580 1595 1610 1625 GAG AAG CCT " GAT GAC ATC AAG AGC ACG TCC AGC CGC CTC TGG CTC AAG TTC GTC Glu Lys Pro Asp Asp He Lys Ser Thr Ser Ser Arg Leu Trp Leu Lys Phe Val 1640 1655 1670 TCT GAC GGG TCC ATT AAC AAA GCG GGC TTT GCC GTC AAC TTC TTC AAA GAG CTG Ser Asp Gly Ser He Asn Lys Ala Gly Phe Ala Val Asn Phe Phe Lys Glu Val 1685 1700 1715 1730 GAC GAG TGC TCT CGG CCC AAC CGC GGG GGC TCT GAG CAG CGG TGC CTC AAC ACC Asp Glu Cys Ser Arg Pro Asn Arg Gly Gly Cys Glu Gin Arg Cys Lsu Asn Thr 1745 1760 1775 CTG GGC AGC. TAC AAG TGC AGC TCT GAC CCC GGG TAC GAG CTG GCC CCA GAC AAG Leu Gly Ser: Tyr Lys Cys Ser Cys Asp Pro Gly Tyr Glu Leu Ala Pro Asp Lys 1790 1805 1820 1835 CGC CGC TCT GAG GCT GCT TCT GGC GGA TTC CTC ACC AAG CTC AAC GGC TCC ATC Arg Arg Cys Glu Ala Ala Cys Gly Gly Phe Leu Thr Lys Leu Asn Gly Ser He 1850 1865 1880 1895 ACC AGC CCG GGC TGG CCC AAG GAG TAC CCC CCC AAC AAG AAC TGC ATC TGG CAG Thr Ser Pro Gly Trp Pro Lys Glu Tyr Pro Pro Asn Lys Asn Cys He Trp Gin 1910 1925 1940 CTG GTG GCC CCC ACC CAG TAC CGC ATC TCC CTG CAG TTT GAC TTC TIT GAG ACA Leu Val Ala Pro Thr Gin Tyr Arg He Ser Leu Gin Phe Asp Phe Phe Glu Thr 1955 1970 1985 2000 GAG GGC AAT GAT GTG TGC AAG TAC GAC TTC GTG GAG GTG CGC ACT GGA CTC ACA Glu Gly Asn Asp Val Cys Lys Tyr Asp Phe Val Glu Val Arg Ser Gly Leu Thr 2015 2030 2045 GCT GAC TCC AAG CTG CAT GGC AAG TTC TCT GCT TCT GAG AAG CCC GAG GTC ATC Ala Asp Ser Lys Leu His Gly Lys Phe Cys Gly Ser Glu Lys Pro Glu Val lie 2060 2075 2090 2105 ACC TCC CAG TAC AAC AAC ATG CGC GTG GAG TTC AAG TCC GAC AAC ACC GTG TCC Thr Ser Gin Tyr Asn Asn MET Arg Val Glu Phe Lys Ser Asp Asn Thr Val Ser 2120 2135 2150 2165 AAA AAG GGC TTC AAG GCC CAC TTC TTC TCA GAA AAG AGG CCA GCT CTG CAG CCC Lys Lys Gly Phe Lys Ala His Phe Phe Ser Glu Lys Arg Pro Ala Leu Gin Pro 2180 2195 22.10 CCT. CGG GGA CGC CCC CAC CAG CTC AAA TTC CGA GTG CAG AAA AGA AAC CGG ACC Pro^Arg Gly Arg Pro His Gin Lsu Lys Phe Arg Val Gin Lys Arg Asn Arg Thr (730) 2225 2235 2245 2255 2265 2275 2285 CCC CAG TGAGGCCTGC CaGGCCTCCC GGACCCCTTG TTACTCAGGA ACCTCACCTT GGACGGAATG Pro Gin 2295 2305 2315 2325 2335 2345 2355 GGATGGGGGC TTCGGTGCCC ACCAACCCCC CACCTCCACT CIGCOOTCC GGCCCACCTC CCTCTGGCCG 2365 2375 2385 2395 2405 2415 2425 GACAGAACTG GTGCTCTCIT CTCCCCACTG TGCCCGTCCG CGGACCGGGG ACCCTTCCCC GTGCCCIACC 2435 2445 2455 2465 2475 2485 2495 CCCTCOCATT TIGATGGTCT CTCTGACATT TCXTCTTGTG AACTAAAAGA CGGACCCCTG CCTCCTGCCT. CTAGA B. hBMP-2: Class I and II The Hindlll-SacI bovine genomic bBMP-2 fragment described in Example IV B. is subcloned into an M13 vector. A 3 P-labeled single-stranded DNA probe is made from a template preparation of this subclone. This probe is used to screen polyadenylated RNAs from various cell and tissue sources as described above in part A. A hybridizing band corresponding to, n mRNA species of approximately 3.8 kb is detected in the lane= containing RNA from the human cell line U-2 OS. The Hindlll-SacI fragment is labeled with 3 P by nick translation and- sed, to screen the nitrocellulose filter replicas of the above-described U-2 OS cDNA library by hybridization in standard hybridization buffer at 65° overnight followed by washing in 1 X SSC, 0.1% SDS at 65°. Twelve duplicate positive clones are picked and replated for secondaries. Duplicate nitrocellulose replicas are made of the secondary plates and both sets hybridized to the bovine genomic probe as the primary screening was performed. One set of filters is then washed in 1 X SSC, 0.1% SDS; the other in 0.1 X SSC, 0.1% SDS at 65°. Two classes of hBMP-2 cDNA clones are evident based on strong (4 recombinants) or weak (7 recombinants) hybridization signals under the more stringent washing conditions (0.1 X SSC, 0.1% SDS) . All 11 recombinant bacteriophage are plaque purified, small scale DNA preparations made from plate lysates of each, and the inserts subcloned into pSP65 and into M13 for sequence analysis. Sequence analysis of the strongly hybridizing clones designated hBMP-2 Class (also known as BMP-2) indicates that they have extensive sequence homology with the sequence given in Table III. These clones are therefore cDNA encoding the human equivalent of the protein encoded by the bBMP-2 gene whose partial sequence is given in Table III. Sequence analysis of the weakly hybridizing recombinants designated hBMP-2 Class II (also known as BMP-4) indicates that they are also quite homologous with the sequence given in Table III at the 3 ' end of their coding regions, but less so in the more 5' regions. Thus they encode a human protein of similar, though not identical, structure to that above. Full length hBMP-2 Class I cDNA clones are obtained in the following manner. The 1.5 kb insert of one of the Class II subclones (II-10-1) is isolated and radioactively labeled by nick-translation. One set of the nitrocellulose rep . licas; of the- U-2 OS cDNA library screened above (50 filters, corresponding to 1,000,000 recombinant bacteriophage) are rehybridized with this probe under stringent conditions (hybridization at 65° in standard hybridization buffer; washing at 6 ' 5° in 0.2 X SSC, 0.1% -SDS). All recombinants which hybridize to the bovine genomic probe which do not hybridize to the Class II probe are picked and plaque purified (10 recombinants) . Plate stocks are made and small scale bacteriophage DNA preparations made. "After subcloning into M13, sequence analysis indicates that 4 of these represent clones which overlap the original Class I clone. One of these, lambda U20S-39, contains an approximately 1.5 kb insert and was deposited with the ATCC on June 16, 1987 under accession number 40345. The partial DNA sequence (compiled from lambda U20S-39 and several other hBMP-2 Class I cDNA recombinants) and derived amino acid sequence are shown below in Table VII. Lambda U20S-39 is expected to contain all of the nucleotide sequence necessary to encode the entire human counterpart of the protein BMP-2 Class II encoded by the bovine gene segment whose partial sequence is presented: in Table III. This human cDNA hBMP-2 Class II contains an open reading frame of 1188 bp, encoding a protein of 396 amino acids. This protein of 396 amino acids has a molecular weight of 45kd based on this amino acid sequence. It is contemplated that this sequence represents the primary translation product. The protein is preceded by a 5 ' untranslated region of 342 bp with stop codons in all frames. The 13: bp region preceding this 5 ' untranslated region represents a linker used in the cDNA cloning procedure. TABLE VII 10 20 30 40 50 60 70 CTCGACTCTA GAGTGTGTCT CAGCACITGG CTGGGGACIT CTTGAACTTG CAGGGAGAAT AACITGCGCA 80 90 100 110 120 130 140 CCCCSCTTTG CGCCGGTGCC TTTGCCCCAG CGGAGCCTGC TTCGCCATCT CCGAGCCCCA CCGCCCCTCC 150 160 170 180 190 200 210 ACTCCTCGGC CTTGCCCGAC ACTGAGACGC TGTTCCCAGC GTGAAAAGAG AGACTGOGCG GCOGGCACCC 220 230 240 250 260 270 280 GGGAGAAGGA GGAGGCAAAG AAAAGGAACG GACaiTCGCT CXII7IGCGCCA GGTCCTTTGA CCAGAGTΓI 290 300 310 320 330 340 350 TCCATCTGGA CXXTCTTTCA ATGGACGTCT CCCCGCGTGC TICTTAGACG GACTGCGGTC TCCTAAAGCT (1) 370 385 400 CGACC ATG GTG GCC GG ACC CGC TCT CTT CTA GCG TTG CTG CTT CCC CA^ MET Val Ala, Gly Thr Arg Cys Leu Leu Ala Leu Leu Leu Pro Gin Val 415 430 445 CTC OS GGC GGC GCG GCT GGC CTC CTT CXG GAG CTG GGC CG^ Leu Leu Gly Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg Arg Lys Phe Ala 460 475 490 • 505 GCG GCG TOG TCG GGC CGC CCC TCA TCC CAG CCC TCT GAC GAG CTC CTG AGC GAG Ala Ala Ser Ser Gly Arg Pro Ser Ser Gin Pro Ser Asp Glu Val Leu Ser Glu 520 535 550 565 TTC GAG TTG CGG CTG CTC AGC ATG TTC GGC CTG AAA CAG AGA CCC ACC CCC AGC Phe Glu Leu Arg Leu Leu Ser MET Phe Gly Leu Lys Gin Arg Pro Thr Pro Ser 580 595 610 AGG GAC GCC GTG GTG CCC CCC TAC ATG CTA GAC CTG TAT CGC AGG CAC TCG GCT Arg Asp Ala Val Val Pro Pro Tyr MET Leu Asp Leu Tyr Arg Arg His Ser Gly 625 640 655 670 CAG CCG GGC TCA CCC GCC CCA GAC CAC CGG TTG GAG AGG GCA GCC AGC CGA GCC Gin Pro Gly Ser Pro Ala Pro Asp His Arg Leu Glu Arg Ala Ala Ser Arg Ala 685 700 715 AAC ACT CTG CGC AGC TTC CAC CAT GAA GAA TCT TTG GAA GAA CTA CCA GAA ACG Asn Thr Val Arg Ser Phe His His Glu Glu Ser Leu Glu Glu Lsu Pro Glu Thr 730 745 760 775 AGT GGG AAA ACA ACC CGG AGA TTC TTC T T AAT TTA ACT TCT ATC CCC ACG GAG Ser Gly Lys Thr Thr Arg Arg Phe Phe Phe Asn Leu Ser Ser He Pro Thr Glu 790 805 820 835 GAG T T ATC ACC TCA GCA GAG CTT CAG CTT TTC CGA GAA CAG ATG CAA GAT GCT Glu Phe He Thr Ser Ala Glu Leu Gin Val Phe Arg Glu Gin MET Gin Asp Ala 850 865 880 TTA GGA AAC AAT AGC ACT TTC CAT CAC CGA ATT AAT ATT TAT GAA ATC ATA AAA Leu Gly Asn Asn Ser Ser Phe His His Arg lie Asn lie Tyr Glu He lie Lys 895 910 925 940 CCT GCA ACA GCC AAC TCG AAA TTC CCC GTG ACC ACT CTT TTG GAC ACC AGG TTG Pro Ala Thr Ala Asn Ser Lys Phe Pro Val Thr Ser Leu Leu Asp Thr Arg Lu 955 970 985 GTG AAT CAG AAT GCA AGC AGG TGG GAA ACT TTT GAT CTC ACC CCC GCT CTG ATG Val Asn Gin Asn Ala Ser Arg Trp Glu Ser Phe Asp Val Thr Pro Ala Val MET 1000 1015 1030 1045 CGG TGG ACT GCA CAG GGA CAC GCC AAC CAT GGA TTC GTG GTG GAA CTG GCC CAC Arg Trp Thr Ala Gin Gly His Ala Asn His Gly Phe Val Val Glu Val Ala His 1060 1075 * 1090 1105 TTG GAG GAG AAA CAA GCT CTC TCC AAG AGA CAT GTT AGG ATA AGC AGG TCT TTG Leu Glu Glu Lys Gin Gly Val Ser Lys Arg His Val Arg He Ser Arg Ser Lu 1120 1135 1150 CAC CAA GAT GAA CAC AGC TGG TCA CAG ATA AGG CCA TTG CTA GTA ACT TTT GGC His Gin Asp Glu His Ser Trp Ser Gin lie Arg Pro Leu Leu Val Thr Phe Gly H65 1180 1195 1210 CAT GAT GGA AAA GGG CAT CCT CTC CAC AAA AGA GAA AAA CGT CAA GCC AAA CAC His Asp Gly Lys Gly His Pro Leu His Lys Arg Glu Lys Arg Gin Ala Lys His 1225 1240 1255 AAA CAG CGG AAA CGC CTT AAG TCC AGC TCT AAG AGA CAC CCT TTG TAC CTG GAC Lys Gin Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg His Pro Lsu Tyr Val Asp 1270 1285 1300 1315 TTC ACT GAC GTG GGG TGG AAT GAC TGG ATT CTG GCT CCC CCG GGG TAT CAC GCC Phe Ser Asp Val Gly Trp Asn Asp Trp lie Val Ala Pro Pro Gly Tyr His Ala 1330 1345 1360 1375 TTT TAC TGC CAC GGA GAA TGC CCT TTT CCT CTG GCT GAT CAT CTG AAC TCC ACT Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala Asp His Lsu Asn Ser Thr 1390 1405 1420 AAT CAT GCC ATT CTT CAG ACG TTG CTC AAC TCT CTT AAC TCT AAG ATT CCT AAG Asn His Ala He Val Gin Thr Leu Val Asn Ser Val Asn Ser Lys He Pro Lys 1435 1450 1465 1480 GCA TGC TCT GTC CCG ACA GAA CTC ACT GCT ATC TCG ATG CTG TAC CTT GAC GAG Ala Cys Cys Val Pro Thr Glu Leu Ser Ala He Ser MET Leu Tyr Leu Asp Glu 1495 1510 1525 AAT GAAAAG GIT GTATTAAAGAAC TAT CAG GAC ATG GTT GTG GAG GCT TCT GGG Asn Glu Lys Val Val Lsu Lys Asn Tyr Gin Asp MET Val Val Glu Gly Cys Gly 1540(396) 1553 1563 1573 1583 1593 1603 TGT CGC TACTACAGCA AAATTAAATA CATAAAIATA TATATATATA TATATITTAG AAAAAAGAAA CysϊArg; AAAA. Full-length hBMP-2Class II human cDNA clones are obtained in the following manner. The 200 bp EcoRI-SacI fragment from the 5' end of the Class II recombinant II-10-1 is isolated from its plasmid subclone, labeled by nick- translation, and hybridized to a set of duplicate nitrocellulose replicas of the U-2 OS cDNA library (25 filters/set; representing 500,000 recombinants). Hybridization and washing are performed under stringent conditions as described above. 16 duplicate positives are picked and replated for secondaries. Nitrocellulose filter replicas of the secondary plates are made and hybridized to an oligonucleotide which was; synthesized to correspond to the sequence of II-10-1 and is of the following sequence: CGGGCGCTCAGGATACTCAAGACCAGTGCTG Hybridization is in standard hybridization buffer AT 50° C with washing at 50° in 1 X SSC, 0.1% SDS. 14 recombinant bacteriophage which hybridize to this oligonucleotide are plaque purified. Plate stocks are made and small scale bacteriophage DNA preparations made. After sucloning 3 of these into M13, sequence analysis indicates that they represent clones which overlap the original Class II clone. One of these, lambda U20S-3, was deposited with the ATCC under accession number 40342 on June 16, 1987. U20S-3 contains an insert of approximately 1.8 kb. The partial DNA- sequence and derived amino acid sequence of U20S-3 are shown below in Table VIII. This clone is expected to contain all of the nucleotide sequence necessary to encode the entire human BMP- 2 Class II protein. This cDNA contains an open reading frame of 1224 bp, encoding a protein of 408 amino acids, preceded by a.5' untranslated region of 394 bp with stop codons in all frames, and contains a 3' untranslated region of 308 bp following the in-frame stop codon. The 8 bp region preceding the 5' untranslated region represents a linker used in the cDNA cloning procedure. This protein of 408 amino acids has molecular weight of 47kd and is contemplated to represent the primary translation product. TABLE VIII 10 20 30 40 50 60 70 CTCTAGAGGG CAGAGGAGGA GGGAGGGAGG GAAGGAGCGC GGAGCCCGGC CCGGAAGCTA GGTGACTGTG 80 90 100 110 120 130 140 GCATCCGAGC TGAGGGACGC GAGCCTGAGA CGCX3GCTGCT GCTCCGGCTG AGTATCTAGC TTGTCTCCCC 150 160 170 180 190 200 210 GATGGGSTTC CCGTCCAAGC TATCTCGAGC CTGCAGCGCC ACAGTCCCCG GCCCTCGCCC AGCTTCACTG 220 230 240 250 260 270 280 CAACCCTTCA GAGGTCCCCA GGAGCTGCTG CTGGCGAGCC CGCTACTGCA GGGACCTATG GAGCCATTCC 290 300 310 320 330 340 350 GTAGTGCCAT CCCGAGCAAC GCACIGCTGC AGCTTCCCTG AGCCITTCCA GCAAGITTCT TCLAAGATTGG 360 370 380 390 400 (1) CTCTCAAGAA TCATGGACTG I AI ATATG CCTTGTTTTC TCTCAAGACA CC ATG ATT CCT MET He Pro 417 " 432 447 462 GCT AAC CGA ATG CTG ATG GTC GTT TTA TTA TGC CAA GTC CTG CTA GGA GGC GCG Gly Asn Arg MET Lsu MET Val Val Leu Leu Cys Gin Val L u Leu Gly Gly Ala 477 492 507 AGC CAT GCT ' AGT TTG ATA CCT GAG ACG GGG AAG AAA AAA GTC GCC GAG ATT CAG Ser His Ala Ser Leu He Pro Glu Thr Gly Lys Lys Lys Val Ala Glu lie Gin 522 537 552 ' 567 GGC CAC GCG GGA GGA CGC CGC TCA GGG CAG AGC CAT GAG CTC CTG CGG GAC TTC Gly His Ala Gly Gly Arg Arg Ser Gly Gin Ser His Glu Leu Leu Arg Asp Phe 582 597 612 627 GAG GCG ACA CTT CTG CAG ATG TTT GGG CTG CGC CGC CGC CCG CAG CCT AGC AAG Glu Ala Thr Leu Leu Gin MET Phe Gly Leu Arg Arg Arg Pro Gin Pro Ser Lys 642 657 672 ACT GCC GTC ATT CCG GAC TAC ATG CGG GAT CTT TAC CGG CTT CAG TCT GGG GAG Ser Ala Val He Pro Asp Tyr MET Arg Asp Leu Tyr Arg Leu Gin Ser Gly Glu 687 702 717 732 GAG GAG GAA GAG CAG ATC CAC AGC ACT GCT CTT GAG TAT CCT GAG CGC CCG GCC Glu Glu Glu Glu Gin lie His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala 747 762 777 AGC CGG GCC AAC ACC GTG AGG AGC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC Ser Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn He 792 807 822 837 CCA GGG ACC ACT GAA AAC TCT GCT TTT CCT TTC CTC TTT AAC CTC AGC AGC ATC Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser He 852 867 882 897 CCT GAG AAC GAG GTG ATC TCC TCT GCA GAG CTT CGG CTC TIC CGG GAG CAG GTG Pro-Glu Asn Glu Val He Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gin Val 912 927 942 GAC CAG GGC CCT GAT TGG GAA AGG GGC TTC CAC CCT ATA AAC ATT TAT GAG CTT Asp.Gin Gly Pro Asp Trp Glu Arg Gly Phe His Arg He Asn lie Tyr Glu Val 957 972 987 1002 ATG AAG CCC CCA GCA GAA GTG GTG CCT GGG CAC CTC ATC ACA CGA CTA CTG GAC MET.Lys Pro Pro Ala Glu Val Val Pro Gly His Leu He Thr Arg Leu Leu Asp 1017 1032 1047 ACG AGA CTG CTC CAC CAC AAT CTG ACA CGG TGG GAA ACT TTT GAT GTG AGC CCT Thr Arg Leu Val His His Asn Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro 1062 1077 1092 1107 GCG GTC CTT CGC TGG ACC CGG GAG AAG CAG CCA AAC TAT GGG CTA GCC ATT GAG Ala Val Leu Arg Trp Thr Arg Glu Lys Gin Pro Asn Tyr Gly Leu Ala He Glu 1122 1137 1152 1167 GTG ACT CAC CTC CAT CAG ACT CGG ACC CAC CAG GGC CAG CAT GTC AGG ATT'AGC Val Thr His Leu His Gin Thr Arg Thr His Gin Gly Gin His Val Arg He Ser 1182 1197 1212 CGA TCG TTA CCT CAA GGG ACT GGG AAT TGG GCC CAG CTC CGG CCC CTC CTG GTC Arg Ser Leu Pro Gin Gly Ser Gly Asn Trp Ala Gin Leu Arg Pro Leu Leu Val 1227 1242 1257 1272 ACC TTT GGC CAT GAT GGC CGG GGC CAT GCC TTG ACC CGA CGC CGG AGG GCC AAG Thr Phe Gly His Asp Gly Arg Gly His Ala Leu Thr Arg Arg Arg Arg Ala Lys 1287 1302 1317 CCT AGC CCT AAG <^ <- C TCA CAG a_G GCCAGGAAGAAG AATAAG AC TGC CGG Arg Ser Pro Lys His His Ser Gin Arg Ala Arg Lys Lys Asn Lys Asn Cys Arg 1332 1347 1362 1377 α^ C_AC TCG CTCTAT GTGGACTTCAGC GAT GTG GGC TG^ ATT GTG Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp He Val 1392 1407 1422 1437 GCC CCA CCA GGC TAC CAG GCC TTC TAC TGC CAT GGG GAC TGC CCC TIT CCA CTG Ala Pro Pro Gly Tyr Gin Ala Phe Tyr Cys His Gly Asp Cys Pro Phe Pro Leu 1452 1467 1482 GCTTGAC CAC CTC AAC TCA ACC AAC CAT GCC ATT GTG CAG ACC CTG GTC AAT TCT Ala.Asp His Leu Asn Ser Thr Asn His Ala He Val Gin Thr Leu Val Asn Ser 149T 1512 1527 1542 GTC AAT TCC ACT ATC CCC AAA GCC TCT TCT GTG CCC ACT GAA CTG ACT GCC ATC Val Asn Ser Ser He Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Serbia He 1557 1572 1587 TCC ATG CTG TAC CTG GAT GAG TAT GAT AAG CTG GTA CTG AAA AAT TAT CAG GAG Ser MET Leu Tyr Lu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gin Glu 1602 1617 (408) 1636 1646 1656 ATG GTA CTA GAG GGA TGT GGG TGC CGC TGAGATCAGG CAGTCCTTGA GGATAGACAG MET " Val Val Glu Gly Cys Gly Cys Arg 1666 1676 1686 1696 1706 1716 1726 ATATACACAC CACACACACA CACCACATAC ACCACACACA CACCTTCCCA TCCACTCACC CACACACTAC 1736 1746 1756 1766 1776 1786 1796 ACAGACTGCT TCCTTATAGC TGGACITTTA TITAAAAAAA AAAAAAAAAA AATGGAAAAA ATCCCTAAAC 1806 1816 1826 1836 1846 1856 1866 AITCACCTTG ACCTTATTTA TGACTTTACG TGCAAATCTT TTGACCATAT TGATCATATA TTTTGACAAA 1876 1886 1896 1906 1916 1926 1936 ATATATTTAT AACTACCTAT TAAAAGAAAA AAAIAAAATG ACTCATTATT TTAAAAAAAA AAAAAAAACT 1946 CTAGACTCGA CGGAATTC The sequences of BMP-2 Class I and II, as well as BMP-3 as shown in Tables III, IV, VII and VIII have significant homology to the beta (B) and beta (A) subunits of the inhibins. The inhibins are a family of hormones which are presently being investigated for use in contraception. See, A. J. Mason et al. Natur . 318:659-663 (1985). To a lesser extent they are also homologous to Mullerian inhibiting substance (MIS : ) , a testicular glycoprotein that causes regression of the:Mullerian duct during development of the male embryo and transforming growth factor-beta (TGF-b) which can inhibit or stimulate growth of cells or cause them to differentiate. Furthermore, the sequence of Table VII encoding hBMP-2 Class II has significant homology to the Drosophila decapentaplegic (DPP-C) locus transcript. See, J. Massague, Cell. 49:437-438 (1987); R. W. Padgett et al, Nature. 325:81-84 (1987); R. L. Cate et al, Cell 45: 685-698 (1986) . It is considered possible therefore that BMP-2 Class II is the human homolog of the protein made from this transcript from this developmental mutant locus. C. BMP-3 Because bovine and human bone growth factor genes are presumed to be significantly homologous, oligonucleotide probes which have been shown to hybridize to the bovine DNA sequence of Table IV.A and IV.B are used to screen a human genomic library A human genomic library (Toole et al., supra) is screened using these probes, and presumptive positives are isolated and DNA sequence obtained as described above. Evidence that this recombinant encodes a portion of the human bone-, inductive factor molecule relies on the bovine/human protein and gene structure homologies. Once a recombinant bacteriophage containing DNA encoding a portion of the human BMP-3 molecule is obtained the human coding sequence is used as a probe as described in Example V (A) to identify a human cell line or tissue which synthesizes BMP-3. mRNA is selected by oligo (dT) cellulose chromatography and cDNA is synthesized and cloned in lambda gtlO by established techniques (Toole et al., supra) . Alternatively, the entire gene encoding this human bone inductive factor can be identified and obtained in additional recombinant clones if necessary. Additional recombinants containing further 3 ' or 5' regions of this human bone inductive factor gene can be obtained by identifying unique DNA sequences at the end(s) of the original clone and using these as probes to rescreen the human genomic library. The gene can then be reassembled in a single plasmid by standard molecular biology techniques and amplified in bacteria. The entire human BMP-3 factor gene can then be transferredto an appropriate expressionvector. The expression vector containing the gene is then transfected into a mammalian cell, e.g. monkey COS cells, where the human gene is transcribed and the RNA correctly spliced. Media from the transfected cells are assayed for bone inductive factor activity as described herein as an indication that the gene is complete. mRNA is obtained from these cells and cDNA synthesized from this mRNA source and cloned. The procedures described above may similarly be employed to isolate other species' bone inductive factor of interest by utilizing the bovine bone inductive factor and/or human bone inductive factor as a probe source. Such other species' bone inductive factor may find similar utility in, inter alia, fracture repair. EXAMPLE VI Expression of Bone Inductive Factors. In order to produce bovine, human or other mammalian bone inductive factors, the DNA encoding it is transferred into an appropriate expression vector and introduced into mammalian cells by conventional genetic engineering techniques. One skilled in the art can construct mammalian expression vectors by employing the sequence of Tables II- VIII or other modified sequences and known vectors, such as pCD [Okaya a et al., Mol. Cell Biol.. 2:161-170 (1982)] and pJL3> pJL4 [Gough et al., EMBO J_ s _, 4:645-653 (1985)]. The transformation of these vectors into appropriate host cells can result in expression of osteoinductive factors. One skilled in the art could manipulate the sequences of Tables II-VIII by eliminating or replacing the mammalian regulatory sequences flanking the coding sequence with bacterial sequences to create bacterial vectors for intracellular or extracellular expression: by bacterial cells. For example, the coding sequences could be further manipulated (e.g. ligated to other known linkers or modified by deleting non-coding sequences there-from- or altering nucleotides therein by other known techniques) . The modified bone inductive factor coding sequence could then be inserted into a known bacterial vector using procedures such as described in T. Taniguchi et al., Proc. Natl Acad. Sci. USA. 77:5230-5233 (1980). This exemplary bacterial vector could then be transformed into bacterial host cells and bone inductive factor expressed thereby. For a strategy for producing extracellular expression of bone inductive factor in bacterial cells., see, e.g. European patent application EPA 177,343. Similar manipulations can be performed for the construction of an insect vector [See, e.g. procedures described in published European patent application 155,476] for expression in insect cells. A yeast vector could also be constructed employing yeast regulatory sequences for intracellular or extracellular expression of the factors of the present invention by yeast cells. [See, e.g., procedures described in published PCT application WO86/00639 and European patent application EPA 123,289] . A method for producing high levels of an osteoinductive factor of the invention from mammalian cells involves the construction of cells containing multiple copies of the heterologous bone inductive factor gene. The heterologous gene can be linked to an amplifiable marker, e.g. the dihydrofolate reductase (DHFR) gene for which cells containing increased gene copies can be selected for propagation in increasing concentrations ofmethotrexate (MTX) accordingto theprocedures of Kaufman and Sharp, J. Mol. Biol.. 159:601-629 (1982). This approach can be employed with a number of different cell types. For example, a plasmid containing a DNA sequence for a bone inductive factor of the invention in operative association with other plasmid sequences enabling expression thereof and the DHFR expression plasmid pAdA26SV(A)3 [Kaufman and Sharp, Mol. Cell. Biol. , 2:1304 (1982) ] can be co-introduced into DHFR-deficient CHO cells, DUKX-BII, by calcium phosphate coprecipitationandtransfection. DHFRexpressingtransformants are selected for growth in alpha media with dialyzed fetal calf serum, and subsequently selected for amplification by growth in increasing concentrations of MTX (sequential steps in 0.02, 0.2, 1.0 and 5uM MTX) as described in Kaufman et al., Mol Cell Biol.. 5:1750 (1983). Transformants are cloned, and biologically active bone inductive factor expression is monitored by rat bone formation assay. Bone inductive factor expression should increase with increasing levels of MTX resistance. Similar procedures can be followed to produce other bone inductive factors. Alternatively, the human gene is expressed directly, as described above. Active bone inductive factor may be produced in bacteria or yeast cells. However the presently preferred expression system for biologically active recom¬ binant human bone inductive factor is stably transformed CHO cells. As one specific example, to produce the human bone inductive factor (hBMP-1) of Example V, the insert of U20S-1 is released from the vector arms by digestion with Sal I and • subcloned into the mammalian expression vector pMT2CX digested with Xho I. Plasmid DNA from this subclone is transfected into COS cells by the DEAE-dextran procedure [Sompayrac and Danna PNAS 7_8_: 7575-7578 (1981) ; Luth an and Magnusson, Nucl.Acids Res. 11: 1295-1308 (1983)]. Serum-free 24 hr. conditioned medium is collected from the cells starting 40- 70 hr. post-transfection. The mammalian expression vector pMT2 Cla-Xho (pMT2 CX) is a derivative of p91023 (b) (Wong et al., Science 228:810-815. 1985) differing from the latter in that it contains the ampicillin resistance gene in place of the tetracycline resistance gene and further contains a Xhol site for insertion of cDNA clones. The functional elements of pMT2' Cla-Xho have been described (Kaufman, R.J., 1985, Proc. Natl. Acad. Sci. USA 8_2:689-693) and include the adenovirus VA. genes, the SV40 origin of replication including the 72 bp enhancer, the adenovirus major late promoter including a 5' splice site and the majority of the adenovirus tripartite leader sequence present on adenovirus late mRNAs, a 3' splice acceptor site, a DHFR insert, the SV40 early polyadenylation site (SV40) , and pBR322 sequences needed for propagation in E'.. coli. Plasmid pMT2 Cla-Xho is obtained by EcoRI digestion of pMT2-VWF, which has been deposited with the American Type Culture Collection (ATCC) , Roσkville, MD (USA) under accession number ATCC 67122. EcoRI digestion excises the cDNA insert present in pMT2-VWF, yielding pMT2 in linear form- which can be ligated and used to transform E. coli HB 101 or DH-5 to ampicillin -resistance. Plasmid pMT2 DNA can be prepared by conventional methods. pMT2CX is then constructed by digesting pMT2 with Eco RV and Xbal, treating the digested DNA with Klenow fragment of DNA polymerase I, and ligating Cla linkers (NEBiolabs, CATCGATG) . This removes bases 2266 to 2421 starting from the Hind III site near the SV40 origin of replication and enhancer sequences of pMT2. Plasmid DNA is then digested with EcoRI, blunted as above, and ligated to an EcoRI adapter, 5• PO4-AATTCCTCGAGAGCT 3 ' 3 » GGAGCTCTCGA 5 « digested with Xhol, and ligated, yielding pMT2 Cla-Xho, which may then be used to transform E. coli to ampicillin resistance. Plasmid- pMT2 Cla-Xho DNA may be prepared by conventional methods. Example VII Biological Activity of Expressed Bone Inductive Factor A. BMP-1 To measure the biological activity of the expressed bone inductive factor (hBMP-1) obtained in Example VI above. The factor is partially purified on a Heparin Sepharose column. 4 ml of transfection supernatant from one 100 mm dish is concentrated approximately 10 fold by ultrafiltration on a YM 10 membrane and then dialyzed against 20mM Tris, 0.15 M NaCl, pH 7.4 (starting buffer). This material is then applied to a 1.1 ml Heparin Sepharose column in "starting buffer. Unbound proteins are removed by an 8 ml wash of starting buffer, and bound proteins, including BMP-1, are desorbed by a 3-4 ml wash of 20 mM Tris, 2.0 M NaCl, pH 7.4. The proteins bound by the Heparin column are concentrated approximately 10-fold on a Centricon 10 and the salt reduced by diafiltration with 0.1% trifluoroacetic acid. The appropriate amount of this solution is mixed with 20 mg of rat matrix and then assayed for in vivo bone and cartilage formation as previously described in Example III. A mock transfection supernatant fractionation is used as a control. The implants containing rat matrix to which specific amounts, of human BMP-1 have been added are removed from rats after seven days and processed for histological evaluation. Representative sections from each implant are stained for the presence of new bone mineral with von Kossa and acid fuschin, and for the presence of cartilage-specific matrix formation using toluidine blue. The types of cells present within the section, as well as the extent to which these cells display phenotype are evaluated. Addition of human BMP-1 to the matrix material resulted in formation of cartilage-like nodules at 7 days post implantation. The chondroblast-type cells were recognizable by shape and expression of metachromatic matrix. The amount of activity observed for human BMP-1 was dependent upon the amount of human BMP-1 protein added to the matrix. Table IX illustrates the dose-response relationship of human BMP-1 protein to the amount of bone induction observed. Table IX IMPLANT NUMBER AMOUNT USED HISTOLOGICAL SCORE (equivalent of ml transfection media) 876-134-1 10 BMP-1 C+2 876-134-2 3 BMP-1 C+l 876-134-3 1 BMP-1 C +/- 876-134-4 10 MOCK C - 876-134-5 3 MOCK C - 876-134-6 1 MOCK C - Cartilage (c) activity was scored on a scale from O(-) to 5. Similar levels of activity are seen in the Heparin Sepharose fractionated COS cell extracts. Partial purification is accomplished in a similar manner as described above except that 6 M urea is included in all the buffers. Further, in a rat bone formation assay as described above, BMP-2 has similarly demonstrated chondrogenic activity. The procedures described above may be employed to isolate other bone inductive factors of interest by utilizing the bovine bone inductive factors and/or human bone inductive factors as a probe source. Such other bone inductive factors may find similar utility in, inter alia, fracture repair. The foregoing descriptions detail presently preferred embodiments of the present invention. Numerous modifications and variations in practice thereof are expected to occur to those skilled in the art upon consideration of these descrip¬ tions. Those modifications and variations are believed to be encompassed within the claims appended hereto. International Application No : PCT/ MICROORGANISMS Option*! Shot In connection with tha mlcroorαanl.m referred to on page , line- of tha deβcrlptlon > A. IDENTIFICATION OF DEPOSIT ' Furthar dapoalta ara Identified on an additional ahaβt j [ * Na a of dapoattar matltutlon i American Type Culture Collection Addraaa-of dapoattary matltutlon (including poatal coda and country) * 12301 Parklawn Drive Rockville, Maryland 20852 USA Name of Referred to on Date of Deposit ATCC No. paσe/line Deposit LP-Hl 40311 29/20 March 4, 1987 bP50 40295 20/3 December 15, 1 J86 bP-21 40310 22/18 March 4 , 1987 U20S-3 40342 44/22 June 16 , 1987 Lambda U2-0S-1 40343 32/33 June 16 , 1987 Lambda BP819 40344 25/23 June 16, 1987 U20S-39 40345 39/21 June 16 , 1987 C. DESICNATEO STATES FOR WHICH INDICATIONS ARE MADE > (if tha indication! ara not lor all designated States) D. SEPARATE FURNISHING OF INDICATIONS • (leave Dlank it not aoplicaolβ) 7hβ indications listed below will be submitted to the International Bureau later » (Specify the general nature of tha indlcatlona e.g., ' Accession NumDer of Oeposit ") E. " i hii sneet was received with tnβ international application ce) The date of receipt (from the applicant) by the International Bureau >° (Authorized Officer) Form PCT. RO 134 (January 1981 )

Claims: WHAT IS: CLAIMED IS: 1., A pharmaceutical composition comprising a protein selected from the group consisting of: (a) BMP-1; (b) BMP-2 Class I; (c) BMP-2 Class II; (d) BMP-3; and mixtures, thereof r in a pharmaceutically acceptable vehicle. 2 . A composition of Claim 1 wherein said protein is BMP- 1.. 3 ~ .. A composition of Claim 1 wherein said protein is BMP- 2- Class I.. 4. A composition of Claim 1 wherein said protein is BMP- 2 Class II. 5. A composition of Claim 1 wherein said protein is BMP- 3. 6. The pharmaceutical composition of Claim 1 further comprising a matrix capable of delivering the composition to the s.ite of the bone defect and providing a structure for inducing bone formation. 7., The composition of Claim 6 wherein saidmatrix comprises a material selected from the group consisting of hydroxyapatite, collagen, polylactic acid and tricalcium phosphate. 8.. A method for inducing bone formation in- a patient in need of same comprising administering to said patient an effective amount of a composition of Claim 1-7. 9. A process for producing BMP-1 comprising culturing in a suitable culture medium a cell line transformed with a DNA sequence encoding BMP-1, said DNA sequence being in relative association with an expression control sequence therefor, and isolating BMP-1 from said culture medium. 1.0. A process according to Claim 9 wherein said DNA sequence comprises substantially the nucleotide sequence of Table VI. 11. A process for producing BMP-2 Class I comprising culturing in a suitable culture medium a cell line transformed with a DNA sequence encoding BMP-2 Class I, said DNA sequence being in relative association with an expression control sequence therefor, and isolating BMP-2 Class I from said culture medium. 12. A process for according to Claim 11 wherein said DNA sequence comprises substantially the nucleotide sequence of Table. VII. 13.. A process for producing BMP-2 Class II comprising culturing in a suitable culture medium a cell line transformed with a DNA sequence encoding BMP-2 Class II, said DNA sequence being in relative association with an expression control sequence therefor, and isolating BMP-2 Class II from said culture medium. 14. A process according to Claim 13 wherein said DNA sequence comprises substantially the nucleotide sequence of Table VIII. 15. A process for producing BMP-3 comprising culturing in a suitable culture medium a cell line transformed with a DNA sequence encoding BMP-3, said DNA sequence being in relative association with an expression control sequence therefor and isolating BMP-3 from said culture medium. 16. A process according to Claim 15 wherein said DNA sequence comprises substantially the nucleotide sequence of Table IVA and IVB. 17. A cDNA sequence encoding BMP-1 comprising substantially the nucleotide sequence of Table VI or a sequence which hybridize thereto under stringent conditions and which upon expression codes for a protein exhibiting substantial properties of BMP-1. 18. A cDNA sequence encoding BMP-2 Class I comprising substantially the nucleotide sequence of Table VII or a sequence which hybridizes thereto under stringent conditions and which upon expression codes for a protein exhibiting substantial properties of BMP-2 Class I. 19. A cDNA sequence encoding BMP-2 Class II comprising substantially the nucleotide sequence of Table VIII or a sequence which hybridizes thereto under stringent conditions and which upon expression codes for a protein exhibiting substantial properties of BMP-2 Class II. 20. A cDNA sequence encoding BMP-3 comprising substantially the nucleotide sequence of Table IVA and IVB or a sequence which hybridizes thereto under stringent conditions and which upon expression codes for a protein exhibiting substantial properties of BMP-3.

Inventors: ROSEN VICKI A, WANG ELIZABETH A, WOZNEY JOHN M, ROSEN, VICKI, A., WANG, ELIZABETH, A., WOZNEY, JOHN, M.
Applicants: GENETICS INST, GENETICS INSTITUTE, INC.
Application year: 1987
Main classification: C07K13
IPC codes: A61K35, A61K38, A61K47, A61L24, A61L27, A61P43, C07K14, C12N1, C12N5, C12N15, C12P21, C12R1